Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I/II Human Clinical Trial of BAG3 Gene Therapy in Dilated Cardiomyopathy (DCM) Patients with Mutations in their BAG3 Gene

Next Previous
Trial Profile

A phase I/II Human Clinical Trial of BAG3 Gene Therapy in Dilated Cardiomyopathy (DCM) Patients with Mutations in their BAG3 Gene

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 26 Mar 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AAV-based-gene-therapy-Renovacor (Primary)
  • Indications Dilated cardiomyopathy
  • Focus Adverse reactions
  • Sponsors Renovacor

Most Recent Events

  • 23 Mar 2021 According to a Renovacor media release, the company anticipates to submit IND in mid-2022 and will begin this trial shortly thereafter.
  • 19 Aug 2019 New trial record
  • 14 Aug 2019 According to a Renovacor media release, proceeds from the series A financing will be used to advance the companys first-of-its-kind gene replacement therapy (BAG3 gene therapy) through filing of an IND in preparation to initiate this human clinical trial in dilated cardiomyopathy (DCM) patients who have mutations in their BAG3 gene.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top